UBS Rates Nuvalent (NUVL) hold, $124 Price Target
Wall Street firms are adjusting their expectations for Nuvalent as shares trade near their 52-week high, a 0.61% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
UBS rated Nuvalent Inc ($NUVL) "hold" with a $124 price target on June 10, 2026.
Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).
NUVL
Nuvalent Inc
Key Points
- UBS lowered its rating on Nuvalent Inc (NUVL) to a hold with a $124 price target on June 10, 2026.
- UBS's $124 price target implies 0.61% upside from Nuvalent Inc's ($NUVL) current $123.25 share price.
- Bernstein followed up on June 24, 2026, by downgrading the stock to Market Perform and setting a $124 target.
- Nuvalent shares recently traded around $123.25, hovering just under the 52-week high of $123.99.
Get $NUVL trade alerts by text
We text you when insiders, Congress or big funds trade $NUVL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent Inc alert may contain errors. Disclosures
UBS and Bernstein Adjust Views on Nuvalent Stock
On June 10, 2026, UBS adjusted its stance on Nuvalent Inc (NUVL) traded on the NGM exchange. Analyst David Dai lowered the rating to hold alongside a price target of $124. The adjustment places the target just a hair above where the shares currently change hands, giving investors a clear look at how Wall Street sees the near-term upside for the clinical-stage biotech firm.
$NUVL price target
Nuvalent Inc daily closes and this analyst's $124 target. Not advice.
Analysts Set New Price Targets
The cautious tone continued later in the month. On June 24, 2026, Bernstein downgraded the stock to Market Perform and lowered its price target to $124 from a prior target of $172. Across the wider analyst community, the stock holds a consensus recommendation key of hold. Nine analysts weigh in with a mean price target of $124, matching the targets set by both UBS and Bernstein.
Nuvalent Stock Trading Near 52-Week Highs
Shares of Nuvalent recently changed hands at $123.25 on Saturday. That price sits right near the 52-week high of $123.99, far above the 52-week low of $71.13. Because the company is not yet profitable, it lacks a traditional P/E ratio, though it carries a forward P/E of -30.85 based on its earnings outlook.
Inside Nuvalent's Pipeline Focus
Nuvalent, Inc. is a Cambridge, Massachusetts-based biotechnology company with 234 employees. Led by CEO Ms. Ruth Adams, the firm focuses on creating targeted cancer treatments. Its pipeline includes drug candidates designed to tackle treatment resistance and brain metastases in patients with specific genetic mutations. As the company moves its clinical trials forward, market watchers will be tracking upcoming data releases and further analyst commentary for signs of shifting momentum.
Related Filing Alerts
Source: UBS's rating change on $NUVL (Jun 10, 2026). Written by software, not financial advice. How we make alerts